Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

Resistance to Antibody-Drug Conjugates Targeting HER2 in Breast Cancer: Molecular Landscape and Future Challenges
Lorenzo Guidi, Gloria Pellizzari, Paolo Tarantino, et al.
Cancers (2023) Vol. 15, Iss. 4, pp. 1130-1130
Open Access | Times Cited: 39

Showing 1-25 of 39 citing articles:

Targeting HER2 heterogeneity in breast and gastrointestinal cancers
Carmine Valenza, Lorenzo Guidi, Elena Battaiotto, et al.
Trends in cancer (2023) Vol. 10, Iss. 2, pp. 113-123
Closed Access | Times Cited: 24
Safety, Efficacy, and Pharmacokinetics of SHR-A1811, a Human Epidermal Growth Factor Receptor 2–Directed Antibody-Drug Conjugate, in Human Epidermal Growth Factor Receptor 2–Expressing or Mutated Advanced Solid Tumors: A Global Phase I Trial
Herui Yao, Min Yan, Zhongsheng Tong, et al.
Journal of Clinical Oncology (2024) Vol. 42, Iss. 29, pp. 3453-3465
Closed Access | Times Cited: 14
Unlocking the Potential: Biomarkers of Response to Antibody-Drug Conjugates
Liliana Ascione, Lorenzo Guidi, Ajay Prakash, et al.
American Society of Clinical Oncology Educational Book (2024) Vol. 44, Iss. 3
Closed Access | Times Cited: 13
Lipid rafts, caveolae, and epidermal growth factor receptor family: friends or foes?
Francesca Ruzzi, Chiara Cappello, Maria Sofia Semprini, et al.
Cell Communication and Signaling (2024) Vol. 22, Iss. 1
Open Access | Times Cited: 11
Antibody–drug conjugates in lung and breast cancer: current evidence and future directions—a position statement from the ETOP IBCSG Partners Foundation
Solange Peters, Sherene Loi, Fabrice André, et al.
Annals of Oncology (2024) Vol. 35, Iss. 7, pp. 607-629
Closed Access | Times Cited: 9
Disitamab vedotin in preclinical models of HER2-positive breast and gastric cancers resistant to trastuzumab emtansine and trastuzumab deruxtecan
Negar Pourjamal, Vadim Le Joncour, György Vereb, et al.
Translational Oncology (2025) Vol. 53, pp. 102284-102284
Open Access | Times Cited: 1
Case report: Near-complete response to neratinib-based treatment in HR-positive HER2-amplified metastatic breast cancer refractory to trastuzumab deruxtecan
Ünal Metin Tokat, Ashkan Adibi, Esranur Aydın, et al.
Frontiers in Oncology (2025) Vol. 14
Open Access | Times Cited: 1
Antibody–Drug Conjugates in Breast Cancer: Ascent to Destiny and Beyond—A 2023 Review
Tian Xiao, Sanji Ali, Danilo Giffoni de Mello Morais Mata, et al.
Current Oncology (2023) Vol. 30, Iss. 7, pp. 6447-6461
Open Access | Times Cited: 18
Biomarkers for Antibody–Drug Conjugates in Solid Tumors
Jalissa Katrini, Laura Boldrini, Celeste Santoro, et al.
Molecular Cancer Therapeutics (2024) Vol. 23, Iss. 4, pp. 436-446
Closed Access | Times Cited: 8
Mechanisms of action and resistance to anti-HER2 antibody-drug conjugates in breast cancer
Khalil Saleh, Rita Khoury, Nadine Khalife, et al.
Cancer Drug Resistance (2024)
Open Access | Times Cited: 8
Antibody–drug conjugates in cancer therapy: mechanisms and clinical studies
Jun He, Xianghua Zeng, Chunmei Wang, et al.
MedComm (2024) Vol. 5, Iss. 8
Open Access | Times Cited: 7
Charting the Course in Sequencing Antibody-Drug Conjugates in Breast Cancer
Giuseppe Saltalamacchia, Rosalba Torrisi, Rita De Sanctis, et al.
Biomedicines (2024) Vol. 12, Iss. 3, pp. 500-500
Open Access | Times Cited: 6
Unveiling the genetic and epigenetic landscape of colorectal cancer: new insights into pathogenic pathways
Humzah Postwala, Yesha Shah, Priyajeet S. Parekh, et al.
Medical Oncology (2023) Vol. 40, Iss. 11
Closed Access | Times Cited: 10
Impacts of genomic alterations on the efficacy of HER2-targeted antibody–drug conjugates in patients with metastatic breast cancer
Riqing Huang, Anqi Hu, Qixiang Rong, et al.
Journal of Translational Medicine (2025) Vol. 23, Iss. 1
Open Access
Targeting PCSK9, through an innovative cVLP-based vaccine, enhanced the therapeutic activity of a cVLP-HER2 vaccine in a preclinical model of HER2-positive mammary carcinoma
Laura Scalambra, Francesca Ruzzi, Olga Maria Pittino, et al.
Journal of Translational Medicine (2025) Vol. 23, Iss. 1
Open Access
LINC01235 Promotes Clonal Evolution through DNA Replication Licensing‐Induced Chromosomal Instability in Breast Cancer
Qi Zhang, Xuliren Wang, Zhibo Shao, et al.
Advanced Science (2025)
Open Access
Utilizing miR-34a-Loaded HER2-Targeting Exosomes to Improve Breast Cancer Treatment: Insights From an Animal Model
Woo Young Sun, Dosang Lee, Jung Hyun Park, et al.
Journal of Breast Cancer (2025) Vol. 28
Open Access
Key Landmark Clinical Trials Transforming the Therapeutic Landscape of Metastatic Breast Cancer: From Precision Medicine to Immunotherapy
Uzma Asghar, Yashna Nadkarni, Ryan Panchal, et al.
IntechOpen eBooks (2025)
Closed Access
Macrophage-targeting combination therapy enhances T-DXd-induced tumor regression
Bingyu Li, Shanlong Wang, Xiaohui Li, et al.
International Immunopharmacology (2025) Vol. 152, pp. 114378-114378
Closed Access
Antibody–Drug Conjugates (ADC) in HER2/neu-Positive Gynecologic Tumors
Blair McNamara, Michelle Greenman, Nicole Pebley, et al.
Molecules (2023) Vol. 28, Iss. 21, pp. 7389-7389
Open Access | Times Cited: 8
Trastuzumab-MMAU Antibody-Auristatin Conjugates: Valine-Glucoserine Linker with Stabilized Maleimide Conjugation Improves In Vivo Efficacy and Tolerability
Shalom D. Goldberg, Tero Satomaa, Olulanu H. Aina, et al.
Molecular Cancer Therapeutics (2024) Vol. 23, Iss. 11, pp. 1530-1543
Closed Access | Times Cited: 2
Epigenetic Reprogramming Potentiates ICAM1 Antibody Drug Conjugates in Preclinical Models of Melanoma
Peng Zhang, Changjuan Tao, Ye Lu, et al.
Advanced Science (2024) Vol. 11, Iss. 30
Open Access | Times Cited: 2
Current status and challenges in HER2 IHC assessment: scoring survey results in Japan
Takashi Sakatani, Hitoshi Tsuda, Masayuki Yoshida, et al.
Breast Cancer Research and Treatment (2024) Vol. 210, Iss. 1, pp. 27-36
Open Access | Times Cited: 2
Navigating the Complexity of Resistance in Lung Cancer Therapy: Mechanisms, Organoid Models, and Strategies for Overcoming Treatment Failure
Da Hyun Kang, Jisoo Lee, Subin Im, et al.
Cancers (2024) Vol. 16, Iss. 23, pp. 3996-3996
Open Access | Times Cited: 2
Exploring DESTINY: the Past, Present, and Future of Trastuzumab Deruxtecan
Azka Ali, Stephanie L. Graff
Current Oncology Reports (2023) Vol. 26, Iss. 1, pp. 1-9
Closed Access | Times Cited: 4
Page 1 - Next Page

Scroll to top